Not medical advice. Cartalax is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
Cartalax (Ala-Glu-Asp, "AED") is a three-amino-acid peptide bioregulator from the Khavinson cytogen family, studied for tissue-specific gene modulation in cartilage and connective-tissue cell models.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Cartalax (Ala-Glu-Asp / AED) is a synthetic short-peptide bioregulator from the Khavinson cytogen family, studied for tissue-specific gene modulation in cartilage and connective-tissue cell cultures.
Peer-reviewed literature typically discusses Cartalax in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Researchers study these compounds for mitochondrial function, nutrient sensing, and cellular energy stress responses -often in ageing or metabolic disease models.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 1–10 mg subcutaneous injection (research-protocol range) · Once daily in short pulsed cycles (e.g. 10–20 days), mirroring published cytogen-peptide schedules · Formal human pharmacokinetic parameters (t½, Vd, bioavailability) have not been published for Cartalax. As a tripeptide (MW 333.30 Da) it is subject to rapid peptidase hydrolysis releasing its constituent amino acids. Subcutaneous and intraperitoneal routes are standard in the published short-peptide literature; oral bioavailability is not characterised. These figures describe the research literature and are not a dosing recommendation.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
Cartalax (Ala-Glu-Asp / AED) is studied as a tissue-specific short-peptide bioregulator focused on cartilage and connective tissue. Research has examined its influence on chondrocyte and fibroblast proliferation and on gene-expression markers tied to connective-tissue ageing, mostly in cell-culture and animal models. It is supplied here for laboratory research only and is not for human use.
AED is the one-letter code for the sequence Alanine-Glutamate-Aspartate — the three amino acids that make up Cartalax. It belongs to the same Khavinson "cytogen" peptide family as Epitalon (AEDG, four residues) and Vesugen (KED). They share a common design idea — very short peptides acting as tissue-specific gene regulators — but each is matched to a different tissue, with Cartalax assigned to cartilage / connective tissue.
The Khavinson bioregulator model proposes that short peptides like Cartalax are small enough to enter the cell nucleus, bind specific promoter sequences in DNA, and modulate the transcription of genes in their target tissue. For Cartalax that target is connective tissue. This is a research hypothesis supported by in-vitro and animal data rather than established human pharmacology.
No controlled human pharmacokinetic or efficacy data for Cartalax specifically has been published. Most of the evidence comes from cell-culture and animal studies on the short-peptide bioregulator family. It remains a research compound, not a validated therapy, and is sold here strictly for laboratory use.
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water or sterile saline, refrigerate at 1–6 °C and protect from light. As a small, simple tripeptide it tolerates standard peptide-handling conditions well within the normal usage window.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside Cartalax.
Primary literature and registries for Cartalax, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: Cartalax, AED, Ala-Glu-Asp, Alanyl-Glutamyl-Aspartate, Khavinson cartilage bioregulator, AED tripeptide, connective-tissue peptide bioregulator